|
|
| | BAY 41-2272 Basic information |
| Product Name: | BAY 41-2272 | | Synonyms: | 5-Cyclopropyl-2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyriMidinaMine;5-Cyclopropyl-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-amine;BAY 41-2272; 256376-24-6; UNII-34A162J6WB; IN1523; BAY-41-2272; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDIN-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3;4-B]PYRIDINE;IN1523;UNII-34A162J6WB;3-(4-Amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3;4-Pyrimidinamine, 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-;Inhibitor,inhibit,Guanylate Cyclase,BAY 41 2272,BAY 412272,BAY 41-2272 | | CAS: | 256376-24-6 | | MF: | C20H17FN6 | | MW: | 360.39 | | EINECS: | | | Product Categories: | Pharmaceuticals, Intermediates & Fine Chemicals, Inhibitors | | Mol File: | 256376-24-6.mol |  |
| | BAY 41-2272 Chemical Properties |
| Melting point | 210.5-211.4 °C | | Boiling point | 496.1±45.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Inert atmosphere,2-8°C | | solubility | DMSO: 26 mg/mL at 60 °C | | form | solid | | pka | 2.71±0.10(Predicted) | | color | white |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | WGK Germany | 3 |
| | BAY 41-2272 Usage And Synthesis |
| Description | Soluble guanylate cyclase (sGC), a receptor for nitric oxide (NO), is a heterodimer consisting of alpha and beta subunits, with the beta subunit featuring a heme-nitric oxide (H-NOX) binding domain. The binding of NO to H-NOX induces sGC to generate the second messenger cGMP. BAY 41-2272 is a pyrazolopyridine compound that acts as an activator of sGC, stimulating activity to a level that would be expected to cause biologically important increases in cGMP at concentrations as low as 10-100 nM. Through this effect, it inhibits platelet aggregation (IC50 = 36 nM), induces relaxation of phenylephrine-preconstricted rabbit aorta rings (IC50 = 304 nM), and reduces proliferation in smooth muscle. BAY 41-2272 is effective in vivo, as it decreases mean arterial blood pressure in hypertensive rats. Unlike another sGC activator, YC-1 , BAY 41-2772 does not inhibit phosphodiesterases. | | Uses | BAY 41-2272 is a soluble guanylate cyclase agonist that activates human mononuclear phagocytes. Inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. | | Definition | ChEBI: BAY 41-2272 is a pyrazolopyridine that is 1H-pyrazolo[3,4-b]pyridine which is substituted by a 2-fluorobenzyl group at position 1 and by a 4-amino-5-cyclopropylpyrimidin-2-yl group at position 3. It is an activator of soluble guanylate cyclase. It has a role as a soluble guanylate cyclase activator, a platelet aggregation inhibitor, a vasodilator agent and an antihypertensive agent. It is a pyrazolopyridine, a member of monofluorobenzenes, an aminopyrimidine and a member of cyclopropanes. | | General Description | A cell-permeable pyrazolopyridinylpyrimidine compound that acts as a selective and potent stimulator of soluble guanylate cyclase (effective dose ~ 0.1 nM to 100 μM using recombinant soluble guanylate cyclase). The mode of activation is NO-independent and appears to be mediated through direct binding to the α1 and α2 subunits. Shown to be effective in treating numerous cardiovascular conditions in animal models. Inhibits phenylephrine-induced constriction of rabbit aortic rings (IC50 = 304 nM) and blocks collagen-induced aggregation of human platelets (IC50 = 36 nM). Does not inhibit phosphodiesterases. | | Biochem/physiol Actions | Cell permeable: yes | | storage | Store at +4°C |
| | BAY 41-2272 Preparation Products And Raw materials |
|